Empagliflozin Desbromo Methoxy Impurity

Empagliflozin Desbromo Methoxy Impurity is a chemical impurity related to the drug Empagliflozin, which is used to treat Type 2 Diabetes. This impurity forms during the synthesis or degradation process when the bromine atom in the original structure is removed (“desbromo”) and a methoxy group is introduced. It is considered a process-related impurity and is monitored in pharmaceutical manufacturing because its presence, even in small amounts, can affect the purity, safety, and efficacy of the final drug product. Strict regulatory guidelines require such impurities to be identified, quantified, and controlled within acceptable limits.